Methotrexate Clearance GWAS
Demographics (1)
- gender - Male or female (phv00195886.v1.p1)
Medications (2)
- Adjusted methotrexate clearance - Methotrexate clearance adjusted for protocol, treatment arm, infusion, gender, genetically determined race; mean clearance among patient population was normalized to zero. (phv00195885.v1.p1)
- average methotrexate clearance - Methotrexate clearance averaged over multiple courses for each patient (phv00195884.v1.p1)
Other (18)
- ANALYTE_TYPE - Analyte type (phv00195890.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00195889.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00195873.v1.p1)
- genetically determined Race - Race genetcially determined using STRUCTURE with genome-wide mapping array (phv00195887.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00195892.v1.p1)
- infusion - Methotrexate 4-hour infusion of a 2g/m2 dose or 24 hour infusion of a 1g/m2 dose (phv00195883.v1.p1)
- IS_TUMOR - Tumor status (phv00195891.v1.p1)
- Protocol - Children's Oncology Group P9904 and P9905 protocols. See Ramsey LB, et. Al. Blool 121(6):898-904, 2013 (PMID:23233662) for details. (phv00195881.v1.p1)
- SAMPLE_ID - De-identified sample ID (phv00195888.v1.p1)
- SAMPLE_ID - Sample ID (phv00195877.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00195878.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00195879.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00195875.v1.p1)
- SUBJECT ID - De-identified subject identifier (phv00195880.v1.p1)
- SUBJECT_ID - Subject ID (phv00195872.v1.p1)
- SUBJECT_ID - Subject ID (phv00195876.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00195874.v1.p1)
- Treatment arm - Treatment arms in COG P9904/P9905 protocols. (phv00195882.v1.p1)